Jane Chow

“Q3 marked another strong quarter for Sarah Bell, as they delivered revenue of $29.3 million, growing approximately 30% year over year. Underline growth was driven by success across both core revenue drivers, adoption by more accounts, and deeper penetration within our install base.”

“So I will put our recent FDA clearance into two groups aligned with our two-pronged strategy. The first groups are the algorithm clearances that include artifact rejection, as well as epileptiform abnormality.”

“So previously, we have the territory managers. They cover more individual accounts. And then we have a hospital system team, but they more cover big national accounts like the HCAs and the Common Spirits.”

“Good afternoon, and thank you all for joining us on our fourth quarter and full year 2025 earnings call.”

“Good afternoon, and thank you all for joining us for our third quarter 2025 earnings call. I'm very pleased to report on another strong quarter as we continue to execute on our key growth initiatives while solidifying our position as the category leader in the Point of Care EEG.”